Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From uniQure N.V.
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Amsterdam Molecular Therapeutics (AMT)
- InoCard GmbH
- uniQure Germany GmbH
- uniQure U.S.A.
- uniQure The Netherlands
- uniQure Inc.